PRESS RELEASE published on 01/29/2024 at 17:40, 2 years 6 months ago Valbiotis presents its 2024 financial communication calendar Valbiotis presents its 2024 financial communication calendar. The company specializing in dietary supplements announces publication dates for the 2023 annual report and 2024 half-year report, as well as the Annual General Meeting Financial Communication Calendar Valbiotis Dietary Supplements Metabolic Diseases Cardiovascular Diseases
PRESS RELEASE published on 11/07/2023 at 17:40, 2 years 9 months ago Valbiotis annonce le succès de l’étude clinique de mode d’action sur TOTUM•63, contre le prédiabète et les stades précoces du diabète de type 2
PRESS RELEASE published on 11/07/2023 at 17:40, 2 years 9 months ago Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
PRESS RELEASE published on 11/06/2023 at 17:40, 2 years 9 months ago Valbiotis : Déclaration mensuelle du nombre d’actions et droits de vote – Octobre 2023
PRESS RELEASE published on 10/04/2023 at 17:40, 2 years 10 months ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
PRESS RELEASE published on 10/02/2023 at 17:40, 2 years 10 months ago VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
PRESS RELEASE published on 10/02/2023 at 17:40, 2 years 10 months ago VALBIOTIS SA : l’étude de Phase II/III REVERSE-IT sélectionnée pour une présentation orale au congrès 2023 de l’EASD, principale société savante européenne pour le diabète
PRESS RELEASE published on 09/28/2023 at 17:40, 2 years 10 months ago Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
PRESS RELEASE published on 09/28/2023 at 17:40, 2 years 10 months ago Valbiotis publie son rapport financier pour le premier semestre 2023 et confirme sa feuille de route stratégique
PRESS RELEASE published on 09/11/2023 at 17:40, 2 years 11 months ago VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
Published on 08/20/2026 at 02:22, 2 hours 47 minutes ago Infrastructure Sterilisation Drilling Begins at Tunkillia
Published on 08/20/2026 at 00:40, 4 hours 29 minutes ago Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Published on 08/19/2026 at 22:00, 7 hours 9 minutes ago Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 8 hours 34 minutes ago Revive Therapeutics Announces Proposed Shares for Debt Settlement
Published on 08/20/2026 at 04:10, 59 minutes ago Shanghai Electric Contributes to World-record Biomethanol Bunkering Operation
Published on 08/20/2026 at 02:44, 2 hours 24 minutes ago Quarterly Report for Q2 and Interim Consolidated Financial Statements with Notes for the period from 1 January to 30 June 2026.
Published on 08/20/2026 at 01:45, 3 hours 24 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Annual results – Delivers on guidance and progresses key strategic actions
Published on 08/18/2026 at 18:00, 1 day 11 hours ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 1 day 11 hours ago Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 1 day 17 hours ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 1 day 17 hours ago GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 9 hours ago Aéroports de Paris S.A - July 2026 traffic figures
